These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12425151)

  • 1. [Cevimeline hydrochloride hydrate (Saligren capsule 30 mg): a review of its pharmacological profiles and clinical potential in xerostomia].
    Shiozawa A
    Nihon Yakurigaku Zasshi; 2002 Oct; 120(4):253-8. PubMed ID: 12425151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation.
    Omori Y; Asari T; Maruyama K; Kusama H; Kojima M; Shibata N
    Arzneimittelforschung; 2003; 53(5):342-50. PubMed ID: 12854361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cevimeline on the immunolocalization of aquaporin-5 and the ultrastructure of salivary glands in Sjögren's syndrome model mice.
    Nishimura H; Yakeishi A; Saga T; Yamaki K
    Kurume Med J; 2009; 56(3-4):39-47. PubMed ID: 20505281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle.
    Arisawa H; Fukui K; Fujise N; Masunaga H
    Arzneimittelforschung; 2002; 52(2):81-8. PubMed ID: 11878203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.
    Petrone D; Condemi JJ; Fife R; Gluck O; Cohen S; Dalgin P
    Arthritis Rheum; 2002 Mar; 46(3):748-54. PubMed ID: 11920411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
    Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
    Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of muscarinic agonists in the treatment of Sjögren's syndrome.
    Fox RI; Konttinen Y; Fisher A
    Clin Immunol; 2001 Dec; 101(3):249-63. PubMed ID: 11726216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study.
    Leung KC; McMillan AS; Wong MC; Leung WK; Mok MY; Lau CS
    Clin Rheumatol; 2008 Apr; 27(4):429-36. PubMed ID: 17899308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunohistochemistry-based study on aquaporin (AQP)-1, 3, 4, 5 and 8 in the parotid glands, submandibular glands and sublingual glands of Sjögren's syndrome mouse models chronically administered cevimeline.
    Nakamura M; Saga T; Watanabe K; Takahashi N; Tabira Y; Kusukawa J; Yamaki K
    Kurume Med J; 2013; 60(1):7-19. PubMed ID: 23925155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of cevimeline hydrochloride in the treatment of dry mouth in patients with Sjögren's syndrome].
    Ogawa N; Shimoyama K; Karasawa H; Fukushima T; Masaki Y; Wano Y; Hirose Y; Sugai S
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Oct; 27(5):330-7. PubMed ID: 15559322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effectiveness of cevimeline hydrochloride on dry cough in Sjögren's syndrome].
    Nishinarita M; Hanzawa M; Iikuni N; Ota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Apr; 27(2):99-102. PubMed ID: 15164930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy prediction of cevimeline in patients with Sjögren's syndrome.
    Yamada H; Nakagawa Y; Wakamatsu E; Sumida T; Yamachika S; Nomura Y; Mishima K; Saito I
    Clin Rheumatol; 2007 Aug; 26(8):1320-7. PubMed ID: 17221146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial.
    Fife RS; Chase WF; Dore RK; Wiesenhutter CW; Lockhart PB; Tindall E; Suen JY
    Arch Intern Med; 2002 Jun; 162(11):1293-300. PubMed ID: 12038948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study.
    Ono M; Takamura E; Shinozaki K; Tsumura T; Hamano T; Yagi Y; Tsubota K
    Am J Ophthalmol; 2004 Jul; 138(1):6-17. PubMed ID: 15234277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors.
    Iga Y; Arisawa H; Ogane N; Saito Y; Tomizuka T; Nakagawa-Yagi Y; Masunaga H; Yasuda H; Miyata N
    Jpn J Pharmacol; 1998 Nov; 78(3):373-80. PubMed ID: 9869272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cevimeline.
    Weber J; Keating GM
    Drugs; 2008; 68(12):1691-8. PubMed ID: 18681491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects.
    Arisawa H; Fukui K; Imai E; Fujise N; Masunaga H
    Arzneimittelforschung; 2002; 52(4):225-32. PubMed ID: 12040964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome.
    Fox RI
    Adv Exp Med Biol; 2002; 506(Pt B):1107-16. PubMed ID: 12614037
    [No Abstract]   [Full Text] [Related]  

  • 19. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 3rd communication: effects on respiratory and cardiovascular systems.
    Arisawa H; Fukui K; Masunaga H
    Arzneimittelforschung; 2002; 52(3):162-7. PubMed ID: 11963642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment.
    Komai K; Shiozawa K; Tanaka Y; Yoshihara R; Tanaka C; Sakai H; Yamane T; Murata M; Tsumiyama K; Hashiramoto A; Shiozawa S
    Mod Rheumatol; 2009; 19(4):416-9. PubMed ID: 19452244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.